Acute Cyclosporin A-Treatment Impairs the Cytosolic Guanylate Cyclase-Mediated Vasodilatation in Rat Thoracic Aorta
Acute Cyclosporin A-Treatment Impairs the Cytosolic Guanylate Cyclase-Mediated Vasodilatation in Rat Thoracic Aorta
- 대한생리학회-대한약리학회
- The Korean Journal of Physiology & Pharmacology
- 제2권 제4호
- : SCOPUS, SCIE, KCI등재
- 1998.01
- 471 - 477 (7 pages)
<P> Cyclosporin A (CsA), a widely used immunosuppressant, is well known to cause nephrotoxicity and hypertension as major side effects. The present study was aimed at investigating the effects of CsA-pretreatment on the activities of cytosolic guanylate cyclase (cGC) in relation to the alteration of relaxant responses in the rat thoracic aorta. CsA (10 ㄍM)-preincubation for 90 min significantly attenuated the vasodilatation induced by sodium nitroprusside (SNP), a cytosolic guanylate cyclase activator, shifting the dose-response curve to the right. The increase in cGMP contents induced by SNP was markedly attenuated by CsA. SNP (1 ㄍM∼1 mM) increased the cGC activity dose-dependently, and the increase was completely abolished by CsA. CsA attenuated the SNP-induced cGC activation dose-dependently. The abolishing effect of CsA-pretreatment on the SNP-induced cGC activation was not affected by washing the preparation, suggesting that the inhibition is irreversible. When CsA was added simultaneously with SNP, cGC activation was not attenuated. 1-(5-isoquinolinylsulfonyl)-2-methyl piperazine (H-7), a protein kinase C (PKC) inhibitor, decreased SNP-induced cGC activation and blocked the CsA-attenuation of cGC activation. These results suggest that CsA directly inhibits cGC participating in the CsA-induced impairment of vasodilatation, and that PKC is involved in the inhibitory action of CsA on cGC.